Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

319 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Inebilizumab reduces neuromyelitis optica spectrum disorder risk independent of FCGR3A polymorphism.
Kim HJ, Aktas O, Patterson KR, Korff S, Kunchok A, Bennett JL, Weinshenker BG, Paul F, Hartung HP, Cimbora D, Smith MA, Mittereder N, Rees WA, She D, Cree BAC. Kim HJ, et al. Among authors: weinshenker bg. Ann Clin Transl Neurol. 2023 Dec;10(12):2413-2420. doi: 10.1002/acn3.51911. Epub 2023 Oct 7. Ann Clin Transl Neurol. 2023. PMID: 37804003 Free PMC article.
Frequency of NMOSD misdiagnosis in a cohort from Latin America: Impact and evaluation of different contributors.
Carnero Contentti E, López PA, Criniti J, Alonso R, Silva B, Luetic G, Correa-Díaz EP, Galleguillos L, Navas C, Soto de Castillo I, Hamuy FDB, Gracia F, Tkachuk V, Weinshenker BG, Rojas JI. Carnero Contentti E, et al. Among authors: weinshenker bg. Mult Scler. 2023 Feb;29(2):277-286. doi: 10.1177/13524585221136259. Epub 2022 Dec 1. Mult Scler. 2023. PMID: 36453614
Safety and efficacy of inebilizumab for the treatment of neuromyelitis optica spectrum disorder: end-of-study results from the open-label period of the N-MOmentum trial.
Cree BAC, Kim HJ, Weinshenker BG, Pittock SJ, Wingerchuk DM, Fujihara K, Paul F, Cutter GR, Marignier R, Green AJ, Aktas O, Hartung HP, She D, Rees W, Smith M, Cimbora D, Katz E, Bennett JL; N-MOmentum study investigators. Cree BAC, et al. Among authors: weinshenker bg. Lancet Neurol. 2024 Jun;23(6):588-602. doi: 10.1016/S1474-4422(24)00077-2. Lancet Neurol. 2024. PMID: 38760098 Clinical Trial.
Microfibrillar-associated protein 4 as a potential marker of acute relapse in inflammatory demyelinating diseases of the central nervous system: Pathological and clinical aspects.
Samadzadeh S, Olesen MN, Wirenfeldt M, Möller S, Misu T, Soelberg K, Frederiksen JL, Heegaard S, Mariotto S, Fujihara K, Ruprecht K, Andersen TL, Marignier R, Lillevang ST, Flanagan EP, Pittock SJ, Kim HJ, Bennett JL, Paul F, Sorensen GL, Weinshenker BG, Lassmann H, Asgari N. Samadzadeh S, et al. Among authors: weinshenker bg. Mult Scler. 2023 Dec;29(14):1721-1735. doi: 10.1177/13524585231200720. Epub 2023 Oct 13. Mult Scler. 2023. PMID: 37830484 Free PMC article.
319 results